Anavex Life Sciences Corp. (AVXL) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Anavex Life Sciences Corp. (NASDAQ: AVXL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.14 (-4.20% 1D, market cap $110.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AVXL ranks #723 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AVXL carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OTLK (Outlook Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $114.0M) and HUMA (Humacyte Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $114.2M). Among the 5-stock peer group, AVXL leads on earnings multiple (N/A) while AVXL leads on capital efficiency (-35.0% ROIC).
Per AVXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001314052), Anavex Life Sciences Corp. generated $143.9M in revenue (-2.8% YoY), -$46.4M in net income, and -$39.0M in free cash flow against $133.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 27.3 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While AVXL currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.07) and Max Pain ($1.20) forces dealer call-delta covering toward $8.34.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Anavex Life Sciences Corp. (AVXL) dropped -4.20% to $1.14, trading at 2% of its 52-week range ($1.14 – $7.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Morningstar report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Investing.com -- Shares of Aevex (NASDAQ: AVXL) fell 5% on Wednesday following reports that the U.S. Navy has suspended new orders for the company’s autonomous drone speedboats over ongoing performance issues.
Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology characterization across pipeline programsNEW YORK, Oct. 20, 2026 (GLOB
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AVXL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AVXL. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Anavex Life Sciences Corp. (AVXL) ranks #723 by composite RQD confidence (32/100, grade E) and #637 by equity capitalization ($110.3M). Within this direct 5-issuer industry benchmark cohort, AVXL leads on earnings valuation at N/A trailing P/E, while AVXL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OTLK currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with AVXL at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AVXL
ACTIVE
Anavex Life Sciences Corp. | E | 32/100 | — | — | -35.0% | -4.20% | $110.3M | Benchmark Subject |
| OTLK Outlook Therapeutics Inc. | D- | 35/100 | — | 4.0% | -35.0% | +0.24% | $114.0M | /otlk-vs-avxl → |
| HUMA Humacyte Inc. | E | 30/100 | — | -30.0% | -35.0% | -3.19% | $114.2M | /huma-vs-avxl → |
| VYGR Voyager Therapeutics Inc. | E | 15/100 | — | — | -35.0% | +3.49% | $106.0M | /vygr-vs-avxl → |
| ENGN enGene Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -5.23% | $102.5M | /engn-vs-avxl → |
In its most recent audited fiscal period (FY2025, filed 2025-09-30), Anavex Life Sciences Corp. (AVXL) reported GAAP revenue of $143.9M (-2.8% vs. FY2024 revenue of $148.1M , and -7.8% cumulative change since FY2023) , GAAP net income of -$46.4M, operating cash flow of -$39.0M, and free cash flow of -$39.0M (-26.7% YoY). On the balance sheet, AVXL closed FY2025 with $133.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $143.9M | -$46.4M | -$39.0M | -$39.0M | $133.0M | — |
| FY2024 (FY) | 2024-09-30 | $148.1M | -$43.0M | -$30.8M | -$30.8M | $124.0M | — |
| FY2023 (FY) | 2023-09-30 | $156.1M | -$47.5M | -$27.8M | -$27.8M | — | — |
As of 2026-11-03, Anavex Life Sciences Corp. (NASDAQ: AVXL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.14 (-4.20% 1D, market cap $110.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AVXL ranks #723 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AVXL carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OTLK (Outlook Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $114.0M) and HUMA (Humacyte Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $114.2M). Among the 5-stock peer group, AVXL leads on earnings multiple (N/A) while AVXL leads on capital efficiency (-35.0% ROIC).
Per AVXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001314052), Anavex Life Sciences Corp. generated $143.9M in revenue (-2.8% YoY), -$46.4M in net income, and -$39.0M in free cash flow against $133.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
AVXL last traded at $1.14 (-4.20% on volume of 1,111,806 shares), positioning the stock -44.93% below its 50-day simple moving average ($2.07) and -62.75% below its 200-day simple moving average ($3.06). Across its 52-week range of $1.14 to $7.94, AVXL sits at the 0.0% percentile with a 14-day RSI of 27.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.28).
Anavex Life Sciences Corp. (AVXL) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.14 (-4.20% 1D, market capitalization $110.3M).
Anavex Life Sciences Corp. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile does not describe the products the company sells, its customers, or its revenue model. Reported revenue is — for each period shown. — for further business description.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Anavex Life Sciences Corp. (AVXL) reported $143.9M in annual revenue (up from $148.1M in FY2024, -2.8% YoY) and -$46.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($156.1M revenue, -$47.5M net income) through FY2025, AVXL scaled operating cash flow to -$39.0M and free cash flow to -$39.0M, backed by $133.0M in total assets against $0 in total debt.
Upstream and downstream dependencies cannot be mapped from the source data. For a prospective investor, the Phase 2a catalyst in Fragile X Syndrome is a potential pipeline milestone, but its ripple effects on partners, suppliers, or sector peers are not identified in the sources. The concurrent securities-related notices are a second-order consideration: their implications for capital access, legal cost, and management attention are not quantified in the source data.
Real-time company headlines, analyst actions, and sector developments for Anavex Life Sciences Corp. (AVXL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Morningstar report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Anavex Life Sciences Corp. (AVXL) market action, institutional positioning, and fundamental catalysts.
Reported cash of $131.7M and an Altman Z-Score of 2.5 provide a balance-sheet cushion, and the Fragile X IND clearance enables a Phase 2a trial.. When you look under the hood at AVXL, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $7.94. My 12M target is $1.51.
Both sides have a point here — AVXL's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Careful chasing AVXL at $1.19. Zero revenue, net losses of -$46.4M, ROIC of -35%, and an RQD score of 32 (grade E) with active securities-fraud notices indicate forensic and cash-generation risk.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.02 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).